文献速递瓣膜病与结构性心脏病血脂与心血管预防

阿托伐他汀对二叶式主动脉瓣扩张及瓣膜钙化进展的影响:BICATOR随机临床试验

Atorvastatin Effect on Aortic Dilatation and Valvular Calcification Progression in Bicuspid Aortic Valve (BICATOR): A Randomized Clinical Trial.
PubMed 文献 · Circulation · 2024-05-28

BICATOR随机临床试验纳入220例非严重瓣膜功能障碍、非严重瓣膜钙化且升主动脉直径≤50 mm的二叶式主动脉瓣患者,随机给予阿托伐他汀20 mg/日或安慰剂治疗3年。阿托伐他汀组低密度脂蛋白胆固醇显著下降,但最大升主动脉直径增长及主动脉瓣钙化评分进展两组间均无显著差异。

要点

  • 阿托伐他汀20 mg/日治疗3年未减缓二叶式主动脉瓣患者升主动脉扩张。
  • 阿托伐他汀未延缓主动脉瓣钙化评分进展或瓣膜功能障碍进展。
  • 尽管低密度脂蛋白胆固醇显著降低,他汀在此人群未显示结构性获益。

核心结论

  • 在无严重瓣膜功能障碍的二叶式主动脉瓣患者中,阿托伐他汀治疗3年未能减少升主动脉扩张和主动脉瓣钙化的进展,尽管低密度脂蛋白胆固醇水平显著降低。

研究设计与样本

  • 随机临床试验纳入220例二叶式主动脉瓣患者(43例女性,年龄46±13岁),随机接受阿托伐他汀20 mg/日或安慰剂治疗3年。
  • 纳入标准为年龄≥18岁、非严重瓣膜功能障碍、非严重瓣膜钙化、升主动脉直径≤50 mm,基线和治疗3年后行计算机断层扫描和超声心动图检查。

主要发现

  • 随访期间28例患者(12.7%)停止药物治疗(阿托伐他汀组15例,安慰剂组13例),192例完成36个月治疗。
  • 阿托伐他汀组低密度脂蛋白胆固醇显著下降(中位数[四分位距],-30 mg/dL [-51.65至-1.75 mg/dL] 对 6 mg/dL [-4至22.5 mg/dL];P<0.001)。
  • 最大升主动脉直径增长两组无差异:阿托伐他汀组0.65 mm(95% CI,0.45-0.85),安慰剂组0.74 mm(95% CI,0.45-1.04)(P=0.613)。
  • 主动脉瓣钙化评分进展(P=0.167)和瓣膜功能障碍进展两组间均无显著差异。

临床怎么用

  • 对于无严重瓣膜功能障碍的二叶式主动脉瓣患者,不应以减缓升主动脉扩张或瓣膜钙化为目的常规使用阿托伐他汀。
  • 他汀治疗决策应基于其他明确适应证(如血脂异常),而非二叶式主动脉瓣本身的结构性进展预防。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ascending aorta dilation and aortic valve degeneration are common complications in patients with bicuspid aortic valve. Several retrospective studies have suggested the benefit of statins in reducing these complications. This study aimed to determine whether atorvastatin treatment is effective in reducing the growth of aortic diameters in bicuspid aortic valve and if it slows the progression of valve calcification. METHODS: In a randomized clinical trial, 220 patients with bicuspid aortic valve (43 women; 46±13 years of age) were included and treated with either 20 mg of atorvastatin per day or placebo for 3 years. Inclusion criteria were ≥18 years of age, nonsevere valvular dysfunction, nonsevere valve calcification, and ascending aorta diameter ≤50 mm. Computed tomography and echocardiography studies were performed at baseline and after 3 years of treatment. RESULTS: During follow-up, 28 patients (12.7%) discontinued medical treatment (15 on atorvastatin and 13 taking placebo). Thus, 192 patients completed the 36 months of treatment. Low-density lipoprotein cholesterol levels decreased significantly in the atorvastatin group (median [interquartile range], -30 mg/dL [-51.65 to -1.75 mg/dL] versus 6 mg/dL [-4, 22.5 mg/dL]; P<0.001). The maximum ascending aorta diameter increased with no differences between groups: 0.65 mm (95% CI, 0.45-0.85) in the atorvastatin group and 0.74 mm (95% CI, 0.45-1.04) in the placebo group (P=0.613). Similarly, no significant differences were found for the progression of the aortic valve calcium score (P=0.167) or valvular dysfunction. CONCLUSIONS: Among patients with bicuspid aortic valve without severe valvular dysfunction, atorvastatin treatment was not effective in reducing the progression of ascending aorta dilation and aortic valve calcification during 3 years of treatment despite a significant reduction in low-density lipoprotein cholesterol levels. REGISTRATION: URL: https://www.clinicaltrialsregister.eu; Unique identifier: 2015-001808-57. URL: https://www.clinicaltrials.gov; Unique identifier: NCT02679261.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Evangelista A, Galian-Gay L, Guala A, et al. Atorvastatin Effect on Aortic Dilatation and Valvular Calcification Progression in Bicuspid Aortic Valve (BICATOR): A Randomized Clinical Trial. Circulation. 2024. PMID: 38804148. doi:10.1161/CIRCULATIONAHA.123.067537

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。